| scholarly article | Q13442814 |
| P2093 | author name string | Ninet Sinaii | |
| Rebecca J Brown | |||
| Kristina I Rother | |||
| P2860 | cites work | Alpha-cells of the endocrine pancreas: 35 years of research but the enigma remains | Q36721554 |
| Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial | Q44333576 | ||
| Insulin secretion in type 1 diabetes | Q44745157 | ||
| Impact of glucagon response on postprandial hyperglycemia in men with impaired glucose tolerance and type 2 diabetes mellitus | Q46672456 | ||
| Suppressibility of glucagon secretion by glucose in juvenile diabetes | Q51667774 | ||
| Meal-Stimulated Glucagon Release Is Associated with Postprandial Blood Glucose Level and Does Not Interfere with Glycemic Control in Children and Adolescents with New-Onset Type 1 Diabetes | Q58224383 | ||
| Abnormal Pancreatic Glucagon Secretion and Postprandial Hyperglycemia In Diabetes Mellitus | Q67430032 | ||
| Endocrine pancreatic response of children with onset of insulin-requiring diabetes before age 3 and after age 5 | Q70240420 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | type-1 diabetes | Q124407 |
| preproinsulin | Q7240673 | ||
| glucagon | Q28163629 | ||
| P304 | page(s) | 1403-1404 | |
| P577 | publication date | 2008-07-01 | |
| P1433 | published in | Diabetes Care | Q5270111 |
| P1476 | title | Too much glucagon, too little insulin: time course of pancreatic islet dysfunction in new-onset type 1 diabetes | |
| P478 | volume | 31 |
| Q35841231 | Achievement of target A1C levels with negligible hypoglycemia and low glucose variability in youth with short-term type 1 diabetes and residual β-cell function |
| Q37670209 | Acute metabolic effects of exenatide in patients with type 1 diabetes with and without residual insulin to oral and intravenous glucose challenges |
| Q37734219 | Adjunct therapy for type 1 diabetes mellitus |
| Q89146312 | Associations of serum glucagon levels with glycemic variability in type 1 diabetes with different disease durations |
| Q37437167 | Beta-cell-mediated signaling predominates over direct alpha-cell signaling in the regulation of glucagon secretion in humans |
| Q37085327 | Blocking of beta-2 adrenergic receptors hastens recovery from hypoglycemia-associated social withdrawal. |
| Q37408191 | C-peptide in the natural history of type 1 diabetes |
| Q93165467 | Characterisation of the endocrine pancreas in type 1 diabetes: islet size is maintained but islet number is markedly reduced |
| Q45384613 | Characterization of residual β cell function in long-standing type 1 diabetes. |
| Q35822130 | Clinical evolution of beta cell function in youth with diabetes: the SEARCH for Diabetes in Youth study |
| Q36014076 | Comparison of Metabolic Outcomes in Children Diagnosed with Type 1 Diabetes Through Research Screening (Diabetes Autoimmunity Study in the Young [DAISY]) Versus in the Community |
| Q48203716 | Decreased α-cell mass and early structural alterations of the exocrine pancreas in patients with type 1 diabetes: An analysis based on the nPOD repository. |
| Q36109086 | Early loss of the glucagon response to hypoglycemia in adolescents with type 1 diabetes |
| Q40542228 | Effect of exenatide on gastric emptying and graft survival in islet allograft recipients |
| Q33646636 | Evolution of abnormal plasma glucagon responses to mixed-meal feedings in youth with type 1 diabetes during the first 2 years after diagnosis |
| Q36796145 | Fibroblast growth factor 21 mediates specific glucagon actions |
| Q57109437 | Glucagon Receptor Signaling Regulates Energy Metabolism via Hepatic Farnesoid X Receptor and Fibroblast Growth Factor 21 |
| Q38821167 | Glucagon in artificial pancreas systems: Potential benefits and safety profile of future chronic use. |
| Q33801143 | Hyperglucagonemia in an animal model of insulin- deficient diabetes: what therapy can improve it? |
| Q42439814 | Increasing glucagon secretion could antagonize the action of exogenous insulin for glycemic control in streptozocin-induced diabetic rhesus monkeys |
| Q38931078 | Increasing the protein quantity in a meal results in dose-dependent effects on postprandial glucose levels in individuals with Type 1 diabetes mellitus. |
| Q36868102 | Lack of association between residual insulin production and glucagon response to hypoglycemia in youth with short duration of type 1 diabetes |
| Q97682134 | Lixisenatide in type 1 diabetes: A randomised control trial of the effect of lixisenatide on post-meal glucose excursions and glucagon in type 1 diabetes patients |
| Q33654881 | Metabolic implications when employing heavy pre- and post-exercise rapid-acting insulin reductions to prevent hypoglycaemia in type 1 diabetes patients: a randomised clinical trial |
| Q37275992 | Metreleptin improves blood glucose in patients with insulin receptor mutations |
| Q35762651 | Minireview: Glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes |
| Q41301765 | Morphological assessment of pancreatic islet hormone content following aerobic exercise training in rats with poorly controlled Type 1 diabetes mellitus |
| Q91564922 | Pancreatic alpha-cell mass in the early-onset and advanced stage of a mouse model of experimental autoimmune diabetes |
| Q36810781 | Paracrine regulation of glucagon secretion: the β/α/δ model |
| Q50049206 | Pramlintide but not Liraglutide suppresses meal-stimulated glucagon responses in type 1 diabetes. |
| Q28085593 | Protein- and diabetes-induced glomerular hyperfiltration: role of glucagon, vasopressin, and urea |
| Q38197230 | Residual C-peptide in type 1 diabetes: what do we really know? |
| Q52798088 | Residual beta-cell function in diabetes children followed and diagnosed in the TEDDY study compared to community controls. |
| Q39035715 | Secondary consequences of beta cell inexcitability: identification and prevention in a murine model of K(ATP)-induced neonatal diabetes mellitus |
| Q53836936 | Sustained treatment with a stable long-acting oxyntomodulin analogue improves metabolic control and islet morphology in an experimental model of type 1 diabetes. |
| Q26800535 | The Role of Dietary Protein and Fat in Glycaemic Control in Type 1 Diabetes: Implications for Intensive Diabetes Management |
| Q44269887 | The Story of Type 1 Diabetes |
| Q33817024 | The influence of exposure to maternal diabetes in utero on the rate of decline in β-cell function among youth with diabetes |
| Q57637770 | The influence of glucagon on postprandial hyperglycaemia in children 5 years after onset of type 1 diabetes |
| Q37801277 | The metabolic actions of glucagon revisited |
| Q35976782 | The metabolic progression to type 1 diabetes as indicated by serial oral glucose tolerance testing in the Diabetes Prevention Trial-type 1. |
| Q26751078 | Using Drosophila to discover mechanisms underlying type 2 diabetes |
Search more.